

eventual use in human risk assessment. Therefore, to begin to address these areas the NTP is sponsoring a workshop with the following objectives:

- Solicit comment on a process for selection of appropriate nominated substances to undergo cancer hazard evaluation in genetically modified or "transgenic" models.
- Solicit comment on issues related to the proper interpretation of results of "transgenic" cancer models, the implications of these findings for public health decisions, and the most appropriate interpretive language to describe the results of such studies to the scientific/regulatory communities and the public.

Preliminary Agenda

- 8 a.m. Registration
 8:30 a.m. Introduction and Welcome
 8:45 a.m. Plenary Session
- Overview of Selected Transgenic Models
 - Experience with Transgenic Models in the NTP Bioassay
 - Workshop Charge
 - Public Comment
- 10 a.m. Break
 10:30 a.m. Breakout Groups
- Group 1: Solicit comment on a process for selection of appropriate nominated substances to undergo cancer hazard evaluation in genetically modified or "transgenic" models.
 - Group 2: Solicit comment on issues related to the proper interpretation of results of "transgenic" cancer models, the implications of these findings for public health decisions, and the most appropriate interpretive language to describe the results of such studies to the scientific/regulatory communities and the public.
- Noon Lunch (on your own)
 1:00 p.m. Breakout Groups continued
 2:30 p.m. Break
 3:15 p.m. Plenary Session
- Breakout Group Reports
 - Open Discussion
- 4:30 p.m. Adjourn

As additional details and materials for this workshop become available, they will be posted on the NTP web site (<http://ntp-server.niehs.nih.gov>) or can be obtained by contacting Ms. Diane Spencer, NTP Liaison and Scientific Review Office (T: 919-541-2759, F: 919-541-0295, spencer2@niehs.nih.gov).

Registration and Public Comment

The workshop is open to the public and interested individuals are invited to attend as observers. The number of observers will be limited only by the

space available. Due to space limitations, persons interested in attending are asked to pre-register by contacting Ms. Spencer (contact information above).

The NTP invites public comment and time is set-aside during the morning session for presentation of oral comments. Persons wishing to make oral comment are asked to contact Ms. Spencer in advance of the meeting and provide contact information (name, affiliation, telephone, e-mail, and sponsoring organization, if any); however, registration for oral comments will also be accepted on-site. Observers are also welcome to participate in the open discussion in the afternoon plenary session.

The NTP also welcomes receipt of written comments. If sending written comments, please include contact information (name, affiliation, telephone, e-mail, and sponsoring organization, if any) and send to Dr. Mary S. Wolfe, NTP Executive Secretary (P.O. Box 12233, MD A3-01, 111 T.W. Alexander Drive, Research Triangle Park, NC 27709 or wolfe@niehs.nih.gov) by Friday, February 14, 2003. Any comments received will be provided to invited attendees at the meeting and made available for the public.

Samuel H. Wilson,

Deputy Director, National Institute of Environmental Health Sciences.

[FR Doc. 03-35 Filed 1-2-03; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Substance Abuse and Mental Health Services Administration

Current List of Laboratories Which Meet Minimum Standards To Engage in Urine Drug Testing for Federal Agencies

AGENCY: Substance Abuse and Mental Health Services Administration, HHS.

ACTION: Notice.

SUMMARY: The Department of Health and Human Services notifies Federal agencies of the laboratories currently certified to meet standards of Subpart C of Mandatory Guidelines for Federal Workplace Drug Testing Programs (59 FR 29916, 29925). A notice listing all currently certified laboratories is published in the **Federal Register** during the first week of each month. If any laboratory's certification is suspended or revoked, the laboratory will be omitted from subsequent lists

until such time as it is restored to full certification under the Guidelines.

If any laboratory has withdrawn from the National Laboratory Certification Program during the past month, it will be listed at the end, and will be omitted from the monthly listing thereafter.

This notice is also available on the Internet at the following Web sites: <http://workplace.samhsa.gov> and <http://www.drugfreeworkplace.gov>.

FOR FURTHER INFORMATION CONTACT: Mrs. Giselle Hersch or Dr. Walter Vogl, Division of Workplace Programs, 5600 Fishers Lane, Rockwall 2 Building, Room 815, Rockville, Maryland 20857; Tel.: (301) 443-6014, Fax: (301) 443-3031.

SUPPLEMENTARY INFORMATION:

Mandatory Guidelines for Federal Workplace Drug Testing were developed in accordance with Executive Order 12564 and section 503 of Public Law 100-71. Subpart C of the Guidelines, "Certification of Laboratories Engaged in Urine Drug Testing for Federal Agencies," sets strict standards which laboratories must meet in order to conduct urine drug testing for Federal agencies. To become certified an applicant laboratory must undergo three rounds of performance testing plus an on-site inspection.

To maintain that certification a laboratory must participate in a quarterly performance testing program plus periodic, on-site inspections.

Laboratories which claim to be in the applicant stage of certification are not to be considered as meeting the minimum requirements expressed in the HHS Guidelines. A laboratory must have its letter of certification from SAMHSA, HHS (formerly: HHS/NIDA) which attests that it has met minimum standards.

In accordance with Subpart C of the Guidelines, the following laboratories meet the minimum standards set forth in the Guidelines:

ACL Laboratories, 8901 W. Lincoln Ave., West Allis, WI 53227, 414-328-7840/800-877-7016, (Formerly: Bayshore Clinical Laboratory)
 ACM Medical Laboratory, Inc., 160 Elmgrove Park, Rochester, NY 14624, 585-429-2264
 Advanced Toxicology Network, 3560 Air Center Cove, Suite 101, Memphis, TN 38118, 901-794-5770/888-290-1150
 Aegis Analytical Laboratories, Inc., 345 Hill Ave., Nashville, TN 37210, 615-255-2400
 Alliance Laboratory Services, 3200 Burnet Ave., Cincinnati, OH 45229, 513-585-6870, (Formerly: Jewish Hospital of Cincinnati, Inc.)

American Medical Laboratories, Inc.,
14225 Newbrook Dr., Chantilly, VA
20151, 703-802-6900

Associated Pathologists Laboratories,
Inc., 4230 South Burnham Ave., Suite
250, Las Vegas, NV 89119-5412, 702-
733-7866/800-433-2750

Baptist Medical Center—Toxicology
Laboratory, 9601 I-630, Exit 7, Little
Rock, AR 72205-7299, 501-202-2783,
(Formerly: Forensic Toxicology
Laboratory Baptist Medical Center)

Clinical Reference Lab, 8433 Quivira
Rd., Lenexa, KS 66215-2802, 800-
445-6917

Cox Health Systems, Department of
Toxicology, 1423 North Jefferson
Ave., Springfield, MO 65802, 800-
876-3652/417-269-3093, (Formerly:
Cox Medical Centers)

Diagnostic Services Inc., dba DSI, 12700
Westlinks Drive, Fort Myers, FL
33913, 239-561-8200/800-735-5416

Doctors Laboratory, Inc., P.O. Box 2658,
2906 Julia Dr., Valdosta, GA 31602,
912-244-4468

DrugProof, Division of Dynacare, 543
South Hull St., Montgomery, AL
36103, 888-777-9497/334-241-0522,
(Formerly: Alabama Reference
Laboratories, Inc.)

DrugProof, Division of Dynacare/
Laboratory of Pathology, LLC, 1229
Madison St., Suite 500, Nordstrom
Medical Tower, Seattle, WA 98104,
206-386-2661/800-898-0180,
(Formerly: Laboratory of Pathology of
Seattle, Inc., DrugProof, Division of
Laboratory of Pathology of Seattle,
Inc.)

DrugScan, Inc., P.O. Box 2969, 1119
Mearns Rd., Warminster, PA 18974,
215-674-9310

Dynacare Kasper Medical Laboratories*,
10150-102 Street, Suite 200,
Edmonton, Alberta, Canada T5J 5E2,
780-451-3702/800-661-9876

ElSohly Laboratories, Inc., 5 Industrial
Park Dr., Oxford, MS 38655, 662-236-
2609

Express Analytical Labs, 3405 7th
Avenue, Suite 106, Marion, IA 52302,
319-377-0500

Gamma-Dynacare Medical
Laboratories*, A Division of the
Gamma-Dynacare Laboratory
Partnership, 245 Pall Mall St.,
London, ONT, Canada N6A 1P4 519-
679-1630

General Medical Laboratories, 36 South
Brooks St., Madison, WI 53715, 608-
267-6225

Kroll Laboratory Specialists, Inc., 1111
Newton St., Gretna, LA 70053, 504-
361-8989/800-433-3823, (Formerly:
Laboratory Specialists, Inc.)

LabOne, Inc., 10101 Renner Blvd.,
Lenexa, KS 66219, 913-888-3927/
800-873-8845, (Formerly: Center for

Laboratory Services, a Division of
LabOne, Inc.)

Laboratory Corporation of America
Holdings, 7207 N. Gessner Road,
Houston, TX 77040, 713-856-8288/
800-800-2387

Laboratory Corporation of America
Holdings, 69 First Ave., Raritan, NJ
08869, 908-526-2400/800-437-4986,
(Formerly: Roche Biomedical
Laboratories, Inc.)

Laboratory Corporation of America
Holdings, 1904 Alexander Drive,
Research Triangle Park, NC 27709,
919-572-6900/800-833-3984,
(Formerly: LabCorp Occupational
Testing Services, Inc., CompuChem
Laboratories, Inc.; CompuChem
Laboratories, Inc., A Subsidiary of
Roche Biomedical Laboratory; Roche
CompuChem Laboratories, Inc., A
Member of the Roche Group)

Laboratory Corporation of America
Holdings, 10788 Roselle Street, San
Diego, CA 92121, 800-882-7272,
(Formerly: Poisonlab, Inc.)

Laboratory Corporation of America
Holdings, 1120 Stateline Road West,
Southaven, MS 38671, 866-827-8042/
800-233-6339, (Formerly: LabCorp
Occupational Testing Services, Inc.,
MedExpress/National Laboratory
Center)

Marshfield Laboratories, Forensic
Toxicology Laboratory, 1000 North
Oak Ave., Marshfield, WI 54449, 715-
389-3734/800-331-3734

MAXXAM Analytics Inc.,* 5540
McAdam Rd., Mississauga, ON,
Canada L4Z 1P1, 905-890-2555,
(Formerly: NOVAMANN (Ontario)
Inc.)

Medical College Hospitals Toxicology
Laboratory, Department of Pathology,

* The Standards Council of Canada (SCC) voted to end its Laboratory Accreditation Program for Substance Abuse (LAPSA) effective May 2, 1998. Laboratories certified through that program were accredited to conduct forensic urine drug testing as required by U.S. Department of Transportation (DOT) regulations. As of that date, the certification of those accredited Canadian laboratories will continue under DOT authority. The responsibility for conducting quarterly performance testing plus periodic on-site inspections of those LAPSA-accredited laboratories was transferred to the U.S. DHHS, with the DHHS' National Laboratory Certification Program (NLCP) contractor continuing to have an active role in the performance testing and laboratory inspection processes. Other Canadian laboratories wishing to be considered for the NLCP may apply directly to the NLCP contractor just as U.S. laboratories do.

Upon finding a Canadian laboratory to be qualified, the DHHS will recommend that DOT certify the laboratory (**Federal Register**, 16 July 1996) as meeting the minimum standards of the "Mandatory Guidelines for Workplace Drug Testing" (59 FR, 9 June 1994, Pages 29908-29931). After receiving the DOT certification, the laboratory will be included in the monthly list of DHHS certified laboratories and participate in the NLCP certification maintenance program.

3000 Arlington Ave., Toledo, OH
43699, 419-383-5213

MedTox Laboratories, Inc., 402 W.
County Rd. D, St. Paul, MN 55112,
651-636-7466/800-832-3244

MetroLab-Legacy Laboratory Services,
1225 NE 2nd Ave., Portland, OR
97232, 503-413-5295/800-950-5295

Minneapolis Veterans Affairs Medical
Center, Forensic Toxicology
Laboratory, 1 Veterans Drive,
Minneapolis, Minnesota 55417, 612-
725-2088

National Toxicology Laboratories, Inc.,
1100 California Ave., Bakersfield, CA
93304, 661-322-4250/800-350-3515

Northwest Drug Testing, a division of
NWT Inc., 1141 E. 3900 South, Salt
Lake City, UT 84124, 801-293-2300/
800-322-3361, (Formerly: NWT Drug
Testing, NorthWest Toxicology, Inc.)

One Source Toxicology Laboratory, Inc.,
1705 Center Street, Deer Park, TX
77536, 713-920-2559, (Formerly:
University of Texas Medical Branch,
Clinical Chemistry Division; UTMB
Pathology-Toxicology Laboratory)

Oregon Medical Laboratories, P.O. Box
972, 722 East 11th Ave., Eugene, OR
97440-0972, 541-687-2134

Pacific Toxicology Laboratories, 6160
Varel Ave., Woodland Hills, CA
91367, 818-598-3110/800-328-6942,
(Formerly: Centinela Hospital Airport
Toxicology Laboratory)

Pathology Associates Medical
Laboratories, 110 West Cliff Drive,
Spokane, WA 99204, 509-755-8991/
800-541-7891 x8991

PharmChem Laboratories, Inc., 4600 N.
Beach, Haltom City, TX 76137, 817-
605-5300, (Formerly: PharmChem
Laboratories, Inc., Texas Division;
Harris Medical Laboratory)

Physicians Reference Laboratory, 7800
West 110th St., Overland Park, KS
66210, 913-339-0372/800-821-3627

Quest Diagnostics Incorporated, 3175
Presidential Dr., Atlanta, GA 30340,
770-452-1590/800-729-6432,
(Formerly: SmithKline Beecham
Clinical Laboratories, SmithKline Bio-
Science Laboratories)

Quest Diagnostics Incorporated, 4770
Regent Blvd., Irving, TX 75063, 800-
824-6152, (Moved from the Dallas
location on 03/31/01; Formerly:
SmithKline Beecham Clinical
Laboratories, SmithKline Bio-Science
Laboratories)

Quest Diagnostics Incorporated, 400
Egypt Rd., Norristown, PA 19403,
610-631-4600/877-642-2216,
(Formerly: SmithKline Beecham
Clinical Laboratories, SmithKline Bio-
Science Laboratories)

Quest Diagnostics Incorporated, 506 E.
State Pkwy., Schaumburg, IL 60173,
800-669-6995/847-885-2010,

(Formerly: SmithKline Beecham Clinical Laboratories, International Toxicology Laboratories)
 Quest Diagnostics Incorporated, 7600 Tyrone Ave., Van Nuys, CA 91405, 818-989-2520/800-877-2520, (Formerly: SmithKline Beecham Clinical Laboratories)
 Scientific Testing Laboratories, Inc., 450 Southlake Blvd., Richmond, VA 23236, 804-378-9130
 S.E.D. Medical Laboratories, 5601 Office Blvd., Albuquerque, NM 87109, 505-727-6300/800-999-5227
 South Bend Medical Foundation, Inc., 530 N. Lafayette Blvd., South Bend, IN 46601, 574-234-4176x276.
 Southwest Laboratories, 2727 W. Baseline Rd., Tempe, AZ 85283, 602-438-8507 / 800-279-0027
 Sparrow Health System, Toxicology Testing Center, St. Lawrence Campus, 1210 W. Saginaw, Lansing, MI 48915, 517-377-0520, (Formerly: St. Lawrence Hospital & Healthcare System)
 St. Anthony Hospital Toxicology Laboratory, 1000 N. Lee St., Oklahoma City, OK 73101, 405-272-7052

Sure-Test Laboratories, Inc., 2900 Broad Avenue, Memphis, Tennessee 38112, 901-474-6028
 Toxicology & Drug Monitoring Laboratory, University of Missouri Hospital & Clinics, 2703 Clark Lane, Suite B, Lower Level, Columbia, MO 65202, 573-882-1273
 Toxicology Testing Service, Inc., 5426 N.W. 79th Ave., Miami, FL 33166, 305-593-2260,
 U.S. Army Forensic Toxicology Drug Testing Laboratory, 2490 Wilson Street, Fort George G. Meade, MD 20755-5235, 301-677-3714

Richard Kopanda,

Executive Officer, SAMHSA.

[FR Doc. 03-141 Filed 1-2-03; 8:45 am]

BILLING CODE 4160-20-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Substance Abuse and Mental Health Services Administration

Fiscal Year (FY) 2003 Funding Opportunities

AGENCY: Substance Abuse and Mental Health Services Administration, HHS.

ACTION: Notice of funding availability for The Centers for the Application of Prevention Technologies (Short Title: CAPTs).

SUMMARY: The Substance Abuse and Mental Health Services Administration (SAMHSA) Center for Substance Abuse Prevention (CSAP) announces the availability of FY 2003 funds for grants for the following activity. This notice is not a complete description of the activity; potential applicants must obtain a copy of the Request for Applications (RFA), including Part I, *The Centers for the Application of Prevention Technologies (SP 03-002) (Short Title: CAPTs)*, and Part II, *General Policies and Procedures Applicable to all SAMHSA Applications for Discretionary Grants and Cooperative Agreements*, before preparing and submitting an application.

Activity	Application deadline	Est. Funds FY 2003	Est. No. of awards	Project period
The Centers for the Application of Prevention Technologies.	March 10, 2003	\$8,000,000	5	5 years.

The actual amount available for the award may vary depending on unanticipated program requirements and actual SAMHSA appropriations. This program is being announced prior to the annual appropriation for FY 2003 for SAMHSA's programs. Applications are invited based on the assumption that sufficient funds will be appropriated for FY 2003 to permit funding of State Training and Evaluation of Evidence-Based Practices grants. This program is being announced in order to allow applicants sufficient time to plan and prepare applications. Solicitation of applications in advance of a final appropriation will also enable the award of appropriated grant funds in an expeditious manner and thus allow prompt implementation and evaluation of promising practices. All applicants are reminded, however, that we cannot guarantee sufficient funds will be appropriated to permit SAMHSA to fund the grants. This program is authorized under Section 516 of the Public Health Service Act. SAMHSA's policies and procedures for peer review and Advisory Council review of grant

and cooperative agreement applications were published in the **Federal Register** (Vol. 58, No. 126) on July 2, 1993.

General Instructions: Applicants must use application form PHS 5161-1 (Rev. 7/00). The application kit contains the two-part application materials (complete programmatic guidance and instructions for preparing and submitting applications), the PHS 5161-1 which includes Standard Form 424 (Face Page), and other documentation and forms. Application kits may be obtained from:

The National Clearinghouse for Alcohol and Drug Information (NCADI): (800) 789-2647 or (800-487-4889 TDD).

The PHS 5161-1 application form and the full text of the grant announcement are also available electronically via SAMHSA's World Wide Web Home Page: <http://www.samhsa.gov> (Click on "Grant Opportunities").

When requesting an application kit, the applicant must specify the particular announcement number for which detailed information is desired. All information necessary to apply, including where to submit applications

and application deadline instructions, are included in the application kit.

Purpose: The Substance Abuse and Mental Health Services Administration (SAMHSA), Center for Substance Abuse Prevention (CSAP) is accepting applications for Fiscal Year 2003 cooperative agreements for five regional Centers for the Application of Prevention Technologies or CAPTs. The CAPTs are SAMHSA/CSAP's primary knowledge application and capacity expansion program supporting CSAP's mission to bring effective substance abuse prevention to every community. As such, the CAPTs form the cornerstone of CSAP's efforts to move science into services. Under the guidance of CSAP, the CAPTs work to expand the capacity of the substance abuse prevention field through the application of effective evidence/science-based programs, practices, and policies within every State prevention service system and community. To accomplish this, the CAPTs provide their clients with timely and effective technical assistance, training, dissemination, and communication